Skip to content

Released Nov 6, 2025, after the close

10-Q filed Nov 6, 2025, 37 days after period end · 0001193125-25-270036

Q3 2025 · 10-Q
Revenue$9.69M+13.8% vs Q3 2024−84.8% vs Q2 2025
Net Income-$56.86MN/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$6.66N/M vs Q3 2024N/M vs Q2 2025
Operating Income-$48,459,000N/M
Operating Cash Flowderived-$38,189,000N/M
Margins · derived
Operating margin-499.9%+297.2 pt vs Q3 2024
Net margin-586.6%−14.0 pt vs Q3 2024

What the release said

The release

Same quarter

MetricQ3 2025Q3 2024Q3 2023Q3 2022
Revenue$9.69M$8.52M$16.92M$25.15M
Net Income-$56.86M-$48.79M-$49.28M-$19.49M
EPS Diluted-$6.66-$0.59-$0.81-$0.37

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR